GR3035050T3 - Method of preparing a viral vector by homologous intermolecular recombination - Google Patents

Method of preparing a viral vector by homologous intermolecular recombination

Info

Publication number
GR3035050T3
GR3035050T3 GR20000402737T GR20000402737T GR3035050T3 GR 3035050 T3 GR3035050 T3 GR 3035050T3 GR 20000402737 T GR20000402737 T GR 20000402737T GR 20000402737 T GR20000402737 T GR 20000402737T GR 3035050 T3 GR3035050 T3 GR 3035050T3
Authority
GR
Greece
Prior art keywords
preparing
viral vector
vector
intermolecular recombination
particle
Prior art date
Application number
GR20000402737T
Other languages
Greek (el)
English (en)
Inventor
Cecile Chartier
Eric Degryse
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9469390&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3035050(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of GR3035050T3 publication Critical patent/GR3035050T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
GR20000402737T 1994-12-01 2000-12-12 Method of preparing a viral vector by homologous intermolecular recombination GR3035050T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9414470A FR2727689A1 (fr) 1994-12-01 1994-12-01 Nouveau procede de preparation d'un vecteur viral
PCT/FR1995/001590 WO1996017070A1 (fr) 1994-12-01 1995-12-01 Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire

Publications (1)

Publication Number Publication Date
GR3035050T3 true GR3035050T3 (en) 2001-03-30

Family

ID=9469390

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000402737T GR3035050T3 (en) 1994-12-01 2000-12-12 Method of preparing a viral vector by homologous intermolecular recombination

Country Status (13)

Country Link
US (3) US6110735A (enExample)
EP (1) EP0742834B9 (enExample)
JP (1) JP3989541B2 (enExample)
AT (1) ATE196507T1 (enExample)
AU (1) AU707208B2 (enExample)
CA (1) CA2182303C (enExample)
DE (2) DE69518910D1 (enExample)
DK (1) DK0742834T4 (enExample)
ES (1) ES2150595T5 (enExample)
FR (1) FR2727689A1 (enExample)
GR (1) GR3035050T3 (enExample)
PT (1) PT742834E (enExample)
WO (1) WO1996017070A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US7670823B1 (en) 1999-03-02 2010-03-02 Life Technologies Corp. Compositions for use in recombinational cloning of nucleic acids
US6720140B1 (en) * 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
ATE256196T1 (de) 1997-06-09 2003-12-15 Genvec Inc Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
AU749856B2 (en) 1997-09-23 2002-07-04 Genvec, Inc. Plasmids for construction of eukaryotic viral vectors
CN100342008C (zh) * 1997-10-24 2007-10-10 茵维特罗根公司 利用具重组位点的核酸进行重组克隆
CN101125873A (zh) * 1997-10-24 2008-02-20 茵维特罗根公司 利用具重组位点的核酸进行重组克隆
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
CA2394099A1 (en) * 1999-12-07 2001-06-14 Genethon Iii Adenovirus vectors for the transfer of genes in targeted cells
CN1757724B (zh) * 1999-12-10 2014-06-11 茵维特罗根公司 具有独特特异性的多个重组位点在重组克隆中的用途
WO2002014495A2 (en) * 2000-08-14 2002-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced homologous recombination mediated by lambda recombination proteins
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
GB0027501D0 (en) * 2000-11-10 2000-12-27 Astrazeneca Ab Vector
JP2004513638A (ja) * 2000-11-10 2004-05-13 アストラゼネカ・アクチエボラーグ ベクター
AU2002361728A1 (en) * 2001-12-14 2003-06-30 President And Fellows Of Harvard College Immunocellular receptors related to neurological disorders
US7521242B2 (en) * 2003-05-09 2009-04-21 The United States Of America As Represented By The Department Of Health And Human Services Host cells deficient for mismatch repair and their use in methods for inducing homologous recombination using single-stranded nucleic acids
EP2404931A1 (en) * 2003-07-02 2012-01-11 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
AU2004257935B2 (en) 2003-07-21 2009-11-19 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
ATE497974T1 (de) 2003-07-21 2011-02-15 Transgene Sa Multifunktionelle cytokine
ATE469984T1 (de) 2003-12-01 2010-06-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US7674621B2 (en) 2004-05-21 2010-03-09 The United States Of America As Represented By The Department Of Health And Human Services Plasmids and phages for homologous recombination and methods of use
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP2484375B1 (en) 2006-09-26 2018-05-23 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
DK2118292T3 (da) 2007-01-30 2011-10-24 Transgene Sa Papillomavirus E2-polypeptid der anvendes til vaccination
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
AU2010205717A1 (en) 2009-01-13 2010-07-22 Transgene Sa Use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
JP5379243B2 (ja) 2009-01-20 2013-12-25 トランジェーヌ、ソシエテ、アノニム 患者を選択するためのバイオマーカーおよびそれに関連する方法
SG2014014021A (en) 2009-03-24 2014-07-30 Transgene Sa Biomarker for monitoring patients
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
US20110015256A1 (en) * 2009-07-16 2011-01-20 Ihab Mamdouh Ishak Sadek Delivery of restriction endonucleases to treat hiv, cancer, and other medical conditions
US9393299B2 (en) 2009-08-07 2016-07-19 Transgene S.A. Composition for treating HBV infection
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US11344619B2 (en) 2016-05-16 2022-05-31 Access To Advanced Health Institute Formulation containing TLR agonist and methods of use
IL315825A (en) 2016-06-01 2024-11-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
HUE064133T2 (hu) 2016-09-20 2024-03-28 Boehringer Ingelheim Vetmedica Gmbh Kutya adenovírus vektor
EP3516064B1 (en) 2016-09-20 2025-04-16 Boehringer Ingelheim Vetmedica GmbH New promoters
UY37406A (es) 2016-09-20 2018-03-23 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de inserción orf70 de ehv
WO2018054822A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018093932A2 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP3612556B8 (en) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
US20200276299A1 (en) 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2019222281A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220403438A1 (en) 2019-10-08 2022-12-22 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
KR20220150353A (ko) 2020-03-05 2022-11-10 네오티엑스 테라퓨틱스 엘티디. 면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
US20210315986A1 (en) 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
US20250352639A1 (en) 2022-04-10 2025-11-20 Immunomic Therapeutics, Inc. Bicistronic LAMP Constructs Comprising Immune Response Enhancing Genes and Methods of Use Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5582362A (en) * 1995-03-31 1996-12-10 Johnson; John R. Center feed toilet paper dispenser

Also Published As

Publication number Publication date
ATE196507T1 (de) 2000-10-15
DE69518910T3 (de) 2006-07-13
US6281000B1 (en) 2001-08-28
ES2150595T5 (es) 2005-12-01
JPH09509330A (ja) 1997-09-22
US7067310B2 (en) 2006-06-27
DE69518910T4 (de) 2006-02-09
ES2150595T3 (es) 2000-12-01
WO1996017070A1 (fr) 1996-06-06
AU707208B2 (en) 1999-07-08
AU4306896A (en) 1996-06-19
EP0742834A1 (fr) 1996-11-20
EP0742834B1 (fr) 2000-09-20
CA2182303A1 (fr) 1996-06-06
DK0742834T4 (da) 2005-08-22
US20020090715A1 (en) 2002-07-11
FR2727689A1 (fr) 1996-06-07
DK0742834T3 (da) 2001-01-29
JP3989541B2 (ja) 2007-10-10
EP0742834B9 (fr) 2005-12-28
CA2182303C (fr) 2005-06-21
US6110735A (en) 2000-08-29
PT742834E (pt) 2001-03-30
FR2727689B1 (enExample) 1997-02-28
EP0742834B2 (fr) 2005-08-03
DE69518910D1 (de) 2000-10-26
DE69518910T2 (de) 2001-03-29

Similar Documents

Publication Publication Date Title
GR3035050T3 (en) Method of preparing a viral vector by homologous intermolecular recombination
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
EP0757717A4 (en) PAPILLOMAVIRUS VACCINE
CZ63995A3 (en) Virus vectors and their use in gene therapy
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
MY111196A (en) Therapeutic aplication of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
IL112289A0 (en) Composition containing nucleic acids, preparation and use
GR3035627T3 (en) A mammalian cytokine, il-11.
GB2335194A (en) Notch
IL122120A (en) Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
GB2335426B (en) EHV-1 Vectors
CA2191750A1 (en) Virosome-mediated intracellular delivery of therapeutic agents
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
EP0452894A3 (en) Human cells for the high expression of genes inserted in episomal recombinant dna, their preparation and their use
GEP20012489B (en) Use of Natural Human α-Interferon
ZA946008B (en) Novel tripeptides useful in immune and cns therapy
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
MX9708111A (es) Lipidos cationicos para terapia genica.